Evidence mapPaperPMID 39449120Full record

Observational studyCardiovascular diabetology2024

Prognostic impact of switching to the 2021 chronic kidney disease epidemiology collaboration creatinine-based equation in Caucasian patients with type 2 diabetes: the Renal Insufficiency and Cardiovascular events (RIACE) Italian Multicenter Study.

Monia Garofolo, Martina Vitale, Giuseppe Penno, Anna Solini, Emanuela Orsi, Valeria Grancini, Enzo Bonora, Cecilia Fondelli, Roberto Trevisan, Monica Vedovato and 3 more

Registry-linked trialAbstract readMulticenter StudyObservational StudyComparative Study
In one paragraph

Observational study in Cardiovascular diabetology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00715481 (Reduced Estimated Glomerular Filtration Rate), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00715481 completednot on this map

Reduced Estimated Glomerular Filtration Rate (eGFR)and Prediction of Cardiovascular Disease and Renal Outcome in Subjects With Type 2 Diabetes: Italian Multicenter Study

TypeobservationalSponsorDiabetic Nephropathy Study GroupRan2008 to 2015Enrolled15,628ConditionsCardiovascular Disease
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Monia GarofoloDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Martina VitaleDepartment of Clinical and Molecular Medicine, "La Sapienza" University, Via di Grottarossa, Rome, 1035-1039 - 00189, Italy.
Giuseppe PennoDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Anna SoliniDepartment of Surgical, Medical, Molecular and Critical Area Pathology, University of Pisa, Pisa, Italy.
Emanuela OrsiDiabetes Unit, Fondazione IRCCS "Cà Granda - Ospedale Maggiore Policlinico", Milan, Italy.
Valeria GranciniDiabetes Unit, Fondazione IRCCS "Cà Granda - Ospedale Maggiore Policlinico", Milan, Italy.
Enzo BonoraDivision of Endocrinology, Diabetes and Metabolism, University and Hospital Trust of Verona, Verona, Italy.
Cecilia FondelliDiabetes Unit, University of Siena, Siena, Italy.
Roberto TrevisanEndocrinology and Diabetes Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy.
Monica VedovatoDepartment of Clinical and Experimental Medicine, University of Padua, Padua, Italy.
Antonio NicolucciCenter for Outcomes Research and Clinical Epidemiology (CORESEARCH), Pescara, Italy.
Giuseppe PuglieseDepartment of Clinical and Molecular Medicine, "La Sapienza" University, Via di Grottarossa, Rome, 1035-1039 - 00189, Italy. giuseppe.pugliese@uniroma1.it.
Renal Insufficiency And Cardiovascular Events (RIACE) Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA Chronic Kidney Disease (CKD) Epidemiology Collaboration (EPI) formula not including a Black race coefficient has been recently developed and is now recommended in the US. The new (2021) equation was shown to yield higher estimated glomerular filtration rate (eGFR) values than the old (2009) one in a non-Black general population sample, thus reclassifying a significant number of individuals to a better eGFR category. However, reclassified individuals were previously shown to have a lower risk of progression to end-stage kidney disease, but higher adjusted risks for all-cause death and morbidity and mortality from cardiovascular disease than those not reclassified. This study evaluated the prognostic impact of switching from the 2009 to the 2021 CKD-EPI equation in non-Black individuals with type 2 diabetes.

methodsThe Renal Insufficiency And Cardiovascular Events (RIACE) was a prospective cohort study enrolling 15,773 Caucasian patients in 19 Italian centers in 2006-2008. Cardiometabolic risk profile, treatments, complications, and comorbidities were assessed at baseline and eGFR was calculated with the two equations. Vital status was retrieved on 31 October 2015 for 15,656 participants (99.3%).

resultsWith the 2021 equation, the eGFR value increased in all patients, except for 293 individuals with a 2009 eGFR ≥ 105 ml·min

conclusionChanging from the 2009 to the 2021 CKD-EPI equation results in higher eGFR and lower CKD prevalence, with a lower risk of death in reclassified patients with an eGFR < 30 ml·min

trial registrationClinicalTrials.gov, NCT00715481, retrospectively registered 15 July, 2008.

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2Diabetic NephropathiesRenal Insufficiency, ChronicAgedBiomarkersCreatinineDecision Support TechniquesFemaleGlomerular Filtration RateHumansItalyKidneyMaleMiddle AgedModels, BiologicalBiomarkersCreatinineAll-cause mortalityChronic kidney disease epidemiology collaboration equationEstimated glomerular filtration rateRaceType 2 diabetes

Identifiers

PMID39449120
PMCPMC11515406

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.